Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: A retrospective study

Clinics

Volumn 65, Issue 6, 2010, Pages 613-619

  Unlu, Ece ^a   Cevikol, Alev ^a   Bal, Burcu ^a   Gonen, Emel ^a   Celik, Ozlem ^a   Kose, Gulşen ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Botulinum toxin injection; Cerebral palsy; Children; GMFM; Spasticity

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; CEREBRAL PALSY; CHILD; FEMALE; HUMAN; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MOTOR PERFORMANCE; PHYSIOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SPASTICITY;

BOTULINUM TOXINS, TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; MOTOR SKILLS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES;

EID: 77954891474     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010000600009     Document Type: Article

References (26)

1. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol. 2001;8:1-20.
2. Bjornson K, Hays R, Graubert C, Price R,Won F, Mc Laughlin JF, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007;120:49-58.
3. Desloovere K, Molenaers G, De Cat J, Pauwels P, Van Campenhout A, Ortibus E, et al. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol. 2007;49:56-61.
4. Molenaers G, Desloovere K, De Cat J, Jonkers I, De Borre L, Pauwels Pt, al. Single event multilevel botulinum toxin A treatment and surgery: similarities and differences. Eur J Neurol. 2001;8:88-97.
5. Hawamdeh ZM, Ibrahim AI, Qudah AAL. Long term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy. Eura Medicophysica. 2007;43:311-8.
6. Matthews JD, Balaban B. Management of spasticity in children with cerebral palsy. Acta Orthop Traumatol Turc. 2009;43:81-6.
7. Weigl D, Arbel N, Katz K, Becker T, Bar-On E. Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals. J Pediatr Orthop. B 2007;16:293-6.
8. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al. Effect of multilevel botulinum toxin A and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol. 2007;36:30-9.
9. Depedibi R, Ünlü E, Çevikol A, Akkaya T, Cakci A, Cerekçi R, et al. Efficacy of botulinum toxin type A in the management of children with cerebral palsy. NeuroRehabilitation. 2008;23:159-205.
10. Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord. 2004;19:162-7.
11. Slawek J, Klimont L. Functional improvement in cerebral palsy patients treated with botulinum toxin injections- preliminary results. Eur J Neurol. 2003;10:313-7.
12. El O, Peker O, Kosay C, Iyilikci L, Bozan O, Berk H. Botulinum toxin type A injection for spasticity in diplegic type cerebral palsy. J Child Neurol. 2006;21:1009-12.
13. Russell DJ, Rosenbaum, PL, Avery LM, Lane M. Gross Motor Function Measure (GMFM-66 and GMFM-88) User's Manual. Clinics in Developmental Medicine. London, UK: Mac Keith Press; 2002.
14. Palisano R, Rosenbaum P, Walters S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214-23.
15. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206-7.
16. Patrick E, Ada L. The Tardieu scale differentiates contracture from spasticity whereas the Ashworth scale is confounded by it. Clin Rehabil. 2006;20:173-82.
17. Albavera-Hernandez C, Rodriguez J, Idrovo AJ. Safety of botulinum toxin type a among children with spasticity secondary to cerebral palsy: a systematic review of randomised clinical trials. Clin Rehabil. 2009;23:394-407.
18. Cardoso ES, Rodrigues BM, Barroso M, Menezes CJ, Lucena RS, Nora DB, et al. Botulinum toxin type A for the treatment of spastic equinus foot in cerebral palsy. Pediatr Neurol. 2006;34:106-9.
19. Nauman M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botilinum toxin type A following long-term use. Eur J Neurol. 2006;13:35-40.
20. Goldstein M. The treatment of cerebral palsy: what we know, what we don't know. J Pediatr. 2004;145:S42-S46.
21. Manganotti P, Zaina F, Falso M, Milanese F, Fiaschi A. Evaluation of botulinum toxin therapy of spastic equinus in paediatric patients with cerebral palsy. J Rehabil Med. 2007;39:115-20.
22. Ross S, Ensberg JR. Relationship between spasticity, strength, gait and the GMFM-66 persons with spastic diplegia cerebral palsy. Arch Phys Med Rehabil. 2007;88:1114-20.
23. Scholtes VA, Dallmeijer AJ, Knol DL Speth LA, Maathuis CG, Jongerius PH, et al. The combined effect of lower-limb multilevel botulinum toxin type A and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil. 2006;87:1551-8.
24. Bakheit AM, Severa S, Cosgrove A, Morton R, Roussounis SH, Doderlein L, et al. Safety profile and efficacy of botulinum toxin A (dysport) in children with muscle spasticity. Dev Med Child Neurol. 2001;43:234-8.
25. Willis AW, Crowner B, Brunstrom JE, Kissel A, Racette B. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol. 2007;49:818-22.
26. Camargo CHF, Teive HAG, Zonta M, Silva GC, Oliveira MR, Roriz MM, et al. Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy. Arch Neuropsiquiatr. 2009;67:62-8.